Drug Profile
Linaprazan glurate - Cinclus Pharma
Alternative Names: SND-001; X-842Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Cinclus Pharma
- Developer Cinclus Pharma; Shanghai Pharmaceutical Group
- Class Anti-inflammatories; Antibacterials; Gastric antisecretories; Small molecules
- Mechanism of Action Potassium-competitive acid blockers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preregistration Oesophagitis
Most Recent Events
- 27 Nov 2023 Cinclus Pharma expects market approval for linaprazan glurate in Oesophageal motility disorders in 2027
- 27 Nov 2023 Cinclus Pharma plans a phase III trial for Oesophageal motility disorders in US, Europe and one additional region in 2024
- 14 Oct 2023 Updated adverse events data from a phase II LEED trial in Oesophagitis presented at the 31st United European Gastroenterology Week (UEG-2023)